The Many Faces of PD: Should We Consider Progression in a More Nuanced Way? Historically, cancer treatments have been graded in large part by the “response rate” they produce, the reflection of the proportion of patients whose cancers demonstrate significant tumor shrinkage on imaging scans. While stable disease, which at least reflects no disease growth, is considered a reasonable, relative victory compared to evidence of the cancer growing, we consider a treatment as failing when the cancer grows. At the same time, in patients who are being monitored off of therapy, evidence… Read More
- #LCSM Chat topic 7/27: Happy birthday #LCSM–four and feisty!
- #LCSM Chat Topic 7/13: Balancing Connection to Others in the Cancer Community with the Risk of Loss
- #LCSM Chat Topic 6/29: When Doctors Disagree
- #LCSM Chat Topic 6/15: Patient Reported Outcomes (PROs)—more effective than some approved cancer drugs for advanced disease
- #LCSM Chat Topic 6/1: Community Grief: Dealing with our Cumulative Losses
#ASCO16 #LCAM14 ALK biomarker cancer treatment plans clinical research clinical trials Drugs EGFR epatients FDA immunotherapy LDCT lung cancer lung cancer awareness month lung cancer risk factors lung cancer screening Medicare coverage of LDCT over-treatment PCORI Screening self-advocacy shared decision making trials World Cancer Day